Guidelines for primary aldosteronism: Uptake by primary care physicians in Europe

Journal of Hypertension

Volumn 34, Issue 11, 2016, Pages 2253-2257

  Mulatero, Paolo ^a   Monticone, Silvia ^a   Burrello, Jacopo ^a   Veglio, Franco ^a   Williams, Tracy A ^a   Funder, John ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Aldosterone; Endocrine hypertension; General practitioners; Primary aldosteronism

Indexed keywords

ALDOSTERONE; RENIN;

ARTICLE; CITY; ESSENTIAL HYPERTENSION; FEMALE; GENERAL PRACTITIONER; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QUESTIONNAIRE; HYPERALDOSTERONISM; STATISTICS AND NUMERICAL DATA;

FEMALE; GERMANY; HUMANS; HYPERALDOSTERONISM; ITALY; MALE; PHYSICIANS, PRIMARY CARE; PRACTICE GUIDELINES AS TOPIC;

EID: 84986193705     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001088     Document Type: Article

References (14)

1. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al., Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: and Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
2. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio-and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98:4826-4833.
3. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62:331-336.
4. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A, Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism\-The Japan Endocrine Society 2009. Endocr J 2011; 58:711-721.
5. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889-1916; [Epub ahead of print].
6. Brown MJ. Personalised medicine for hypertension. BMJ 2011; 343:d4697.
7. Brown MJ. Clinical value of plasma renin estimation in the management of hypertension. Am J Hypertens 2014; 27:1013-1016.
8. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies-a review of the current literature. Horm Metab Res 2012; 44:157-162.
9. Helber A, Wambach G, Hummerich W, Bonner G, Meurer KA, Kaufmann W. Evidence for a subgroup of essential hypertensives with nonsuppressible excretion of aldosterone during sodium loading. Klin Wochenschr 1980; 58:439-447.
10. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
11. Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M, et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 2013; 28:1787-1793.
12. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89:2736-2740.
13. Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011; 41:1227-1236.
14. Markou A, Sertedaki A, Kaltsas G, Androulakis II, Marakaki C, Pappa T, et al. Stress induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab 2015; 100:2857-2864.